Literature DB >> 19966180

Substitution of serine for proline in the active center of type 2 iodothyronine deiodinase substantially alters its in vitro biochemical properties with dithiothreitol but not its function in intact cells.

Iuri Martin Goemann1, Balázs Gereben, John W Harney, Bo Zhu, Ana Luiza Maia, P Reed Larsen.   

Abstract

T(4) must be activated by its monodeiodination to T(3) by type 1 or 2 iodothyronine deiodinase (D1 and D2). Recent studies show that despite an approximately 2000-fold higher Michaelis constant (K(m); T(4)) for D1 than for D2 using dithiothreitol (DTT) as cofactor, D1 expressed in intact cells produces T(3) at free T(4) concentrations many orders of magnitude below its K(m). To understand the factors regulating D1 and D2 catalysis in vivo, we studied a mutant D2 with a proline at position 135 of the active center of D2 replaced with a serine, as found in D1. The P135S D2 enzyme has many D1-like properties, a K(m) (T(4)) in the micromolar range, ping-pong kinetics with DTT, and sensitivity to 6n-propylthiouracil (PTU) in vitro. Unexpectedly, when the P135S D2 was expressed in HEK-293 cells and exposed to 2-200 pm free T(4), the rate of T(4) to T(3) conversion was identical with D2 and conversion was insensitive to PTU. Using glutathione as a cofactor in vitro resulted in a marked decrease in the K(m) (T(4)) (as also occurs for D1), it showed sequential kinetics with T(4) and it was sensitive to PTU but was resistant when HEK-293 cytosol was used as a cofactor. Thus, the in vivo catalytic properties of the P135S D2 mutant are more accurately predicted from in vitro studies with weak reducing agents, such as glutathione or endogenous cofactors, than by those with DTT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19966180      PMCID: PMC2817617          DOI: 10.1210/en.2009-0980

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  33 in total

1.  Kinetic characteristics of a thioredoxin-activated rat hepatic and renal low-Km iodothyronine 5'-deiodinase.

Authors:  G B Bhat; K Iwase; B C Hummel; P G Walfish
Journal:  Biochem J       Date:  1989-03-15       Impact factor: 3.857

2.  The effects and interactions of substrates, inhibitors, and the cellular thiol-disulfide balance on the regulation of type II iodothyronine 5'-deiodinase.

Authors:  D L St Germain
Journal:  Endocrinology       Date:  1988-05       Impact factor: 4.736

3.  The cDNA for the type I iodothyronine 5'-deiodinase encodes an enzyme manifesting both high Km and low Km activity. Evidence that rat liver and kidney contain a single enzyme which converts thyroxine to 3,5,3'-triiodothyronine.

Authors:  J Sharifi; D L St Germain
Journal:  J Biol Chem       Date:  1992-06-25       Impact factor: 5.157

4.  Molecular biological and biochemical characterization of the human type 2 selenodeiodinase.

Authors:  D Salvatore; T Bartha; J W Harney; P R Larsen
Journal:  Endocrinology       Date:  1996-08       Impact factor: 4.736

5.  Kinetic evidence suggesting two mechanisms for iodothyronine 5'-deiodination in rat cerebral cortex.

Authors:  T J Visser; J L Leonard; M M Kaplan; P R Larsen
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

6.  Regulation of iodothyronine 5'-deiodinases: effects of thiol blockers and altered substrate levels in vivo and in vitro.

Authors:  A Goswami; I N Rosenberg
Journal:  Endocrinology       Date:  1990-05       Impact factor: 4.736

7.  Evidence for two pathways of iodothyronine 5'-deiodination in rat pituitary that differ in kinetics, propylthiouracil sensitivity, and response to hypothyroidism.

Authors:  T J Visser; M M Kaplan; J L Leonard; P R Larsen
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

8.  Type I iodothyronine deiodinase is a selenocysteine-containing enzyme.

Authors:  M J Berry; L Banu; P R Larsen
Journal:  Nature       Date:  1991-01-31       Impact factor: 49.962

9.  Effects of glutathione on iodothyronine 5'-deiodinase activity.

Authors:  A Goswami; I N Rosenberg
Journal:  Endocrinology       Date:  1988-07       Impact factor: 4.736

10.  Selenocysteine confers the biochemical properties characteristic of the type I iodothyronine deiodinase.

Authors:  M J Berry; J D Kieffer; J W Harney; P R Larsen
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

View more
  6 in total

1.  Maternal thimerosal exposure results in aberrant cerebellar oxidative stress, thyroid hormone metabolism, and motor behavior in rat pups; sex- and strain-dependent effects.

Authors:  Z L Sulkowski; T Chen; S Midha; A M Zavacki; Elizabeth M Sajdel-Sulkowska
Journal:  Cerebellum       Date:  2012-06       Impact factor: 3.847

2.  Catalysis leads to posttranslational inactivation of the type 1 deiodinase and alters its conformation.

Authors:  Bo Zhu; Ashutosh Shrivastava; Cristina Luongo; Ting Chen; John W Harney; Alessandro Marsili; Thuy-Van Tran; Anulika Bhadouria; Radhika Mopala; Amanda I Steen; P Reed Larsen; Ann Marie Zavacki
Journal:  J Endocrinol       Date:  2012-04-27       Impact factor: 4.286

3.  IL-6 promotes nonthyroidal illness syndrome by blocking thyroxine activation while promoting thyroid hormone inactivation in human cells.

Authors:  Simone Magagnin Wajner; Iuri Martin Goemann; Ana Laura Bueno; P Reed Larsen; Ana Luiza Maia
Journal:  J Clin Invest       Date:  2011-04-11       Impact factor: 14.808

4.  A new ABC half-transporter in Leishmania major is involved in resistance to antimony.

Authors:  J I Manzano; R García-Hernández; S Castanys; F Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

5.  Intrinsic expression of a multiexon type 3 deiodinase gene controls zebrafish embryo size.

Authors:  Cuicui Guo; Xia Chen; Huaidong Song; Michelle A Maynard; Yi Zhou; Alexei V Lobanov; Vadim N Gladyshev; Jared J Ganis; David Wiley; Rebecca H Jugo; Nicholas Y Lee; Luciana A Castroneves; Leonard I Zon; Thomas S Scanlan; Henry A Feldman; Stephen A Huang
Journal:  Endocrinology       Date:  2014-07-08       Impact factor: 4.736

6.  New Insights toward the Acute Non-Thyroidal Illness Syndrome.

Authors:  Simone Magagnin Wajner; Ana Luiza Maia
Journal:  Front Endocrinol (Lausanne)       Date:  2012-01-26       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.